Lead Product(s): Ziritaxestat
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: GLPG1690
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Gilead Sciences
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 10, 2021
The decision is based on the recommendations of the Independent Data Monitoring Committee (IDMC). Patients continued on their standard of care background treatment and were randomized on to either 200 mg or 600 mg ziritaxestat once daily or placebo.